![]() |
市場調査レポート
商品コード
1540897
バイオマーカー技術市場レポート:検査タイプ、適応症、製品、技術、用途、地域別、2024~2032年Biomarker Technologies Market Report by Test Type, Indication, Product, Technology (Polymerase Chain Reaction, Next Generation Sequencing, Immunoassay, and Others), Application, and Region 2024-2032 |
||||||
カスタマイズ可能
|
バイオマーカー技術市場レポート:検査タイプ、適応症、製品、技術、用途、地域別、2024~2032年 |
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2~3営業日
|
世界のバイオマーカー技術市場規模は2023年に402億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに1,134億米ドルに達し、2024~2032年の間に11.8%の成長率(CAGR)を示すと予測しています。同市場は、医療、医薬品、診断におけるアプリケーションの増加、精密医療や疾患検出への関心の高まり、非侵襲的診断法に対する需要の高まりに牽引され、着実な成長を遂げています。
市場の成長と規模市場は現在、医療、医薬品、診断における用途の増加に後押しされ、安定した成長を遂げています。さらに、バイオマーカー技術の研究開発(R&D)プロセスへの統合がこの安定した成長をさらに後押しし、医療、医薬品、診断の進歩における極めて重要な役割を強化しています。
非侵襲的診断法に対する需要の高まり:非侵襲的診断法に対する需要の高まり:非侵襲的診断法は、患者に優しく、正確であり、侵襲的な処置を必要とせずに病気を発見できる有効性があります。
産業用途:医療、製薬、診断など多様な産業から高い需要があり、その汎用性と広範な採用が注目されています。
地域別動向:北米は、堅牢なインフラ、研究開発への多額の投資、医療イノベーションへの強い注力により、バイオマーカー技術市場をリードしています。
競合情勢:市場は、主要企業が技術革新と市場シェア拡大に注力する激しい競合によって特徴付けられ、バイオマーカー技術の継続的な進歩をもたらしています。
課題と機会:規制上のハードルが課題となる一方で、個別化医療と診断の飛躍的進歩が約束され、業界参入企業にエキサイティングな機会を提供しています。
将来の展望バイオマーカー技術市場の将来は、特に個別化医療と疾患検出の強化のセグメントで有望と考えられます。
精密医療への需要の高まり
精密医療への需要の高まりは、バイオマーカー技術市場の大きな原動力です。精密医療は、医療におけるパラダイムシフトを意味し、患者固有の遺伝子、分子、臨床的特徴に基づいた個別化治療戦略の提供を目指しています。バイオマーカーは、この変革において極めて重要な役割を果たしています。バイオマーカーは、体内の様々な生物学的プロセスを反映する測定可能な指標です。プレシジョンメディシンの文脈では、特定の疾患サブタイプを特定し、疾患の進行を予測し、最も効果的な治療アプローチを決定するための重要なツールとして機能します。バイオマーカーを分析することで、医療専門家は個々の患者に合わせた介入を行い、潜在的な副作用を最小限に抑えながら治療成果を最適化することができます。プレシジョン・メディシンの最も魅力的な側面のひとつは、がん治療に革命をもたらす可能性です。バイオマーカー技術により、腫瘍医は腫瘍内の遺伝子変異やタンパク質マーカーを特定することができ、がんの根本的な分子ドライバーに特異的に対処する標的療法の選択が可能になります。これにより治療が成功する可能性が高まり、試行錯誤的なアプローチの必要性が減るため、効果のない治療や不必要な毒性から患者を免れることができ、市場の成長に拍車がかかります。
オミックス技術の進歩
オミックス技術の進歩は、バイオマーカー技術市場のもう一つの重要なドライバーです。オミクスには、ゲノミクス、プロテオミクス、メタボロミクスなどさまざまな科学セグメントが含まれ、それぞれがバイオマーカーの発見と開発において重要な役割を果たしています。ゲノミクスは、個人のDNAの完全なセットを研究するもので、病気に関連する遺伝的変異や突然変異について洞察を記載しています。DNA配列決定技術の継続的な進歩により、ゲノムの解析がより迅速かつコスト効率よく行われるようになり、様々な疾患と関連する数多くの遺伝子バイオマーカーが同定されるようになりました。このような豊富なゲノムデータは、個別化医療や標的療法の開発の可能性を広げています。プロテオミクスは、生体システム内のタンパク質の研究に焦点を当てています。質量分析とその他の革新的なプロテオミクス技術により、研究者は疾患や治療反応に関連する特定のタンパク質バイオマーカーを同定することができます。これらのバイオマーカーは、病気の診断、モニタリング、薬剤開発の改善に大いに役立つと期待されています。メタボロミクスは、生体サンプル中の低分子化合物や代謝産物を調べ、代謝経路や代謝異常について明らかにします。その結果、オミックス技術の進歩はバイオマーカーのツールボックスを充実させ続け、新たなバイオマーカーの発見を容易にし、疾患に対する理解を深め、診断学と医薬品開発におけるイノベーションを推進しています。
慢性疾患の負担増
慢性疾患の負担の増大は、バイオマーカー技術市場の成長を促進する重要な要因です。心血管疾患、糖尿病、がん、呼吸器疾患などの慢性疾患は、世界の健康課題となっています。人口の高齢化、ライフスタイルの変化、環境要因などの要因が、これらの疾患の有病率上昇に寄与しています。バイオマーカー技術は、慢性疾患との戦いにおける重要なツールとして台頭してきました。バイオマーカーは早期かつ正確な発見の可能性を提供し、効果的な疾病管理と患者の転帰の改善に不可欠です。バイオマーカーは、多くの場合、臨床症状が現れる前に、慢性疾患の発症や進行を示す可能性のある体内の微妙な変化を特定することができます。この早期発見により、医療専門家は迅速に介入し、個別化された治療計画を実施し、疾患の進行をより注意深く監視することができます。慢性疾患の負担が世界的に増加し続ける中、早期発見、正確なモニタリング、個別化された治療戦略をサポートするバイオマーカー技術への需要が高まっています。
The global biomarker technologies market size reached US$ 40.2 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 113.4 Billion by 2032, exhibiting a growth rate (CAGR) of 11.8% during 2024-2032. The market is experiencing steady growth, driven by increasing applications in healthcare, pharmaceuticals, and diagnostics, coupled with a heightening focus on precision medicine and disease detection and the rising demand for non-invasive diagnostic methods.
Market Growth and Size: The market is currently witnessing stable growth, fueled by its increasing applications in healthcare, pharmaceuticals, and diagnostics. Additionally, the integration of biomarker technologies into research and development (R&D) processes further fuels this stable growth, enhancing their pivotal role in advancing healthcare, pharmaceuticals, and diagnostics.
Rising Demand for Non-Invasive Diagnostic Methods: The market witnesses an increasing demand for non-invasive diagnostic methods, driven by their patient-friendly nature, accuracy, and effectiveness in detecting diseases without the need for invasive procedures.
Industry Applications: The market is experiencing high demand from diverse industries, including healthcare, pharmaceuticals, and diagnostics, highlighting their versatility and widespread adoption.
Geographical Trends: North America leads the biomarker technologies market due to its robust infrastructure, significant investments in research and development, and a strong focus on healthcare innovation.
Competitive Landscape: The market is characterized by intense competition with key players focusing on innovation and expanding their market share, resulting in continuous advancements in biomarker technology.
Challenges and Opportunities: While regulatory hurdles present challenges, it also promises of personalized medicine and diagnostic breakthroughs that offers exciting opportunities for industry players.
Future Outlook: The future of the biomarker technologies market looks promising, especially in the realms of personalized medicine and enhanced disease detection.
Growing demand for precision medicine
The growing demand for precision medicine is a maior driving force in the biomarker technologies market. Precision medicine represents a paradigm shift in healthcare, aiming to provide personalized treatment strategies for patients based on their unique genetic, molecular, and clinical characteristics. Biomarkers play a pivotal role in this transformation. They are measurable indicators that reflect various biological processes within the body. In the context of precision medicine, they serve as crucial tools for identifying specific disease subtypes, predicting disease progression, and determining the most effective treatment approaches. By analyzing biomarkers, healthcare professionals can tailor interventions to individual patients, optimizing therapeutic outcomes while minimizing potential side effects. One of the most compelling aspects of precision medicine is its potential to revolutionize cancer care. Biomarker technologies allow oncologists to identify genetic mutations and protein markers in tumors, enabling the selection of targeted therapies that specifically address the underlying molecular drivers of cancer. This increases the chances of successful treatment and reduces the need for trial-and-error approaches, sparing patients from ineffective therapies and unnecessary toxicity, thereby fueling market growth.
Advancements in omics technologies
Advancements in omics technologies represent another significant driver in the biomarker technologies market. Omics encompasses various scientific disciplines, including genomics, proteomics, and metabolomics, each of which plays a crucial role in biomarker discovery and development. Genomics involves the study of an individual's complete set of DNA, providing insights into genetic variations and mutations associated with diseases. Ongoing advancements in DNA sequencing technologies have made it faster and more cost-effective to analyze the genome, leading to the identification of numerous genetic biomarkers linked to various conditions. This wealth of genomic data expands the potential for personalized medicine and the development of targeted therapies. Proteomics focuses on the study of proteins within biological systems. Mass spectrometry and other innovative proteomic techniques enable researchers to identify specific protein biomarkers associated with diseases or treatment responses. These biomarkers hold immense promise for improving disease diagnosis, monitoring, and drug development. Metabolomics examines the small molecules and metabolites in biological samples, shedding light on metabolic pathways and dysregulations. As a result, advancements in omics technologies continue to enrich the biomarker toolbox, facilitating the discovery of new biomarkers, enhancing our understanding of diseases, and driving innovation in diagnostics and drug development.
Increasing burden of chronic diseases
The escalating burden of chronic diseases is a significant factor propelling the growth of the biomarker technologies market. Chronic diseases, such as cardiovascular diseases, diabetes, cancer, and respiratory disorders, are a growing global health challenge. Factors like aging populations, lifestyle changes, and environmental factors contribute to the increasing prevalence of these conditions. Biomarker technologies have emerged as critical tools in the battle against chronic diseases. They offer the potential for early and accurate detection, which is crucial for effective disease management and improved patient outcomes. Biomarkers can identify subtle changes in the body that may indicate the onset or progression of a chronic disease, often before clinical symptoms manifest. This early detection empowers healthcare professionals to intervene promptly, implement personalized treatment plans, and monitor disease progression more closely. As the burden of chronic diseases continues to rise globally, there has been a heightened demand for biomarker technologies that support early detection, precise monitoring, and personalized treatment strategies.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on indication, product, technology and application.
Solid Biopsy
Liquid Biopsy
Liquid biopsy accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the market based on the test type. This includes solid biopsy and liquid biopsy. According to the report, liquid biopsy represented the largest segment.
Liquid biopsy has emerged as a transformative force in the biomarker technologies market. This non-invasive method involves analyzing biomarkers present in bodily fluids, such as blood or urine, to detect diseases, particularly cancer. Liquid biopsies offer numerous advantages, including early disease detection, real-time monitoring, and the ability to track treatment response. They reduce the need for invasive procedures and provide valuable information on tumor heterogeneity. As the demand for less invasive and more accessible diagnostic methods increases, liquid biopsies are driving the market further by expanding applications beyond traditional tissue-based biopsies and revolutionizing the field of diagnostics. Their potential to improve patient care and outcomes makes them a key market driver.
Solid biopsy methods involve the extraction of tissue samples from tumors or other abnormal growths for analysis. Solid biopsies provide essential biomarker data that guide treatment decisions, especially in cancer care. They also enable the identification of specific genetic, protein, or molecular markers, aiding in the selection of targeted therapies and predicting treatment responses. As precision medicine gains prominence, solid biopsy-derived biomarkers become indispensable, contributing to the market growth. Advancements in solid biopsy techniques, such as minimally invasive procedures, improve patient comfort and further fuel their adoption rate.
Cancer
Infectious Diseases
Autoimmune Disorders
Cardiovascular Disorders
Others
Cancer holds the largest share in the industry
A detailed breakup and analysis of the market based on the indication have also been provided in the report. This includes cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and others. According to the report, cancer accounted for the largest market share.
Biomarker technologies are instrumental in the fight against cancer, providing essential tools for early detection, precise diagnosis, and tailored treatment strategies. They enable the identification of specific genetic and molecular markers, improving patient outcomes and driving substantial market growth in the oncology sector. They also play a crucial role in infectious disease management by facilitating rapid and accurate pathogen detection, monitoring treatment responses, and aiding in epidemiological studies, contributing significantly to the market's expansion, particularly in the context of global health crises.
Biomarker technologies are pivotal in diagnosing and monitoring autoimmune disorders, offering insights into disease progression and treatment efficacy, thus driving their adoption and furthering research in autoimmune disease management.
Biomarkers are indispensable in assessing cardiovascular health and risk factors. Their use in early diagnosis, monitoring, and personalized treatment plans fuels the demand for biomarker technologies, leading to advancements in cardiovascular care and fostering market growth.
Consumables
Assay
Reagent
Instruments
Consumables represent the leading market segment
The report has provided a detailed breakup and analysis of the market based on the product. This includes consumables, assay, reagent, and instruments. According to the report, consumables represented the largest segment.
Consumables, including sample collection kits and containers, are vital components of biomarker technology workflows. They are essential for collecting and preserving biological samples, making them indispensable for research, diagnostics, and drug development. The steady demand for these consumables ensures a consistent revenue stream in the biomarker technologies market.
Assays are at the heart of biomarker analysis. They encompass a wide range of techniques, such as ELISA and PCR, used to detect and quantify specific biomarkers. The development of innovative assay methods and kits further catalyzed market growth as they enable more precise and efficient biomarker detection.
Reagents are essential chemical compounds used in various stages of biomarker analysis. They play a critical role in sample preparation, labeling, and detection. The continuous need for high-quality reagents, especially for emerging biomarkers, fuels market demand, making reagents a lucrative segment.
Biomarker detection instruments, such as mass spectrometers and PCR machines, are the technological backbone of biomarker analysis. Advances in instrument capabilities, including sensitivity and throughput, significantly impact market growth. As research and diagnostic needs evolve, there has been a rise in the demand for cutting-edge biomarker detection instruments.
Polymerase Chain Reaction (PCR)
Next Generation Sequencing (NGS)
Immunoassay
Others
Immunoassay accounts for the majority of market share
The report has provided a detailed breakup and analysis of the market based on the technology. This includes polymerase chain reaction (PCR), next generation sequencing (NGS), immunoassay, and others. According to the report, immunoassay represented the largest segment.
Immunoassays are key for detecting protein biomarkers. They offer specificity, making them crucial in clinical diagnostics and research. Constant innovation in immunoassay platforms and reagents continues to propel the biomarker technologies market forward, enhancing biomarker detection sensitivity and precision.
Polymerase Chain Reaction (PCR) technology revolutionized biomarker analysis by enabling the amplification of DNA sequences. It plays a pivotal role in identifying genetic biomarkers, offering high specificity and sensitivity. Its versatility in applications, from disease diagnostics to gene expression analysis, ensures its enduring importance in the biomarker technologies market.
Next Generation Sequencing (NGS) technology enables comprehensive genomic and transcriptomic analysis. It contributes to biomarker discovery by identifying genetic variations associated with diseases. Its ability to process large datasets rapidly has accelerated research, making NGS a major driving force in biomarker-related advancements.
Drug Discovery
Clinical Diagnostics
Personalized Medicine
Drug discovery represents the leading market segment
The report has provided a detailed breakup and analysis of the market based on the application. This includes drug discovery, clinical diagnostics, and personalized medicine. According to the report, drug discovery represented the largest segment.
Biomarker technologies are indispensable in drug discovery, aiding in target identification, validation, and efficacy assessment. They streamline the drug development process by identifying potential therapeutic targets and predicting drug responses, reducing costs and accelerating time to market.
In clinical diagnostics, biomarkers play a pivotal role in disease diagnosis, prognosis, and treatment monitoring. Their use enhances healthcare by enabling early disease detection and personalized treatment plans, spurring the adoption of biomarker technologies in clinical settings, ultimately improving patient outcomes.
Biomarker technologies are the cornerstone of personalized medicine, allowing healthcare providers to tailor treatments based on individual patient profiles. This approach improves treatment efficacy, reduces adverse effects, and fosters patient-centric healthcare, thus fueling the growth of biomarker technologies in personalized medicine applications, revolutionizing healthcare delivery.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest biomarker technologies market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share since the region boasts a robust infrastructure, significant R&D investments, and a focus on healthcare innovation. The region's commitment to cutting-edge research and clinical applications positions it as a key driver of biomarker technology advancement.
Asia Pacific is also an expanding market for biomarker technologies owing to increasing healthcare investments, growing research capabilities, and a rising burden of chronic diseases. The region's emphasis on precision medicine and personalized healthcare drives demand for biomarker-based diagnostics and treatment strategies.
Europe's biomarker technologies market benefits from strong collaborations between academia and industry. It thrives on the continent's commitment to healthcare innovation, making it a prominent player in biomarker research and application development.
Biomarker technologies are rapidly gaining traction in the Middle East and Africa, supported by a growing demand for improved healthcare solutions. The region's increasing healthcare expenditure and heightened focus on disease prevention contribute to the adoption of biomarker-based diagnostics.
Latin America exhibits a growing biomarker technologies market, fueled by the rising prevalence of chronic diseases and a growing awareness of personalized medicine. The region's expanding healthcare infrastructure and research initiatives are driving the demand for biomarker-based solutions, making it a notable contributor to market growth.
Various key players in the market are actively engaging innovation and strategic partnerships to maintain their competitive edge. They are also investing in research and development to enhance the sensitivity and specificity of biomarker detection methods. Additionally, these companies are expanding their product portfolios to cover a broader range of biomarkers and applications, catering to the growing demand for personalized medicine. Collaborations with academic institutions and pharmaceutical companies are common, fostering the discovery and validation of novel biomarkers. Moreover, these market leaders are focused on complying with regulatory standards to ensure the safety and effectiveness of their biomarker-based products, ultimately shaping the future of diagnostics and treatment in healthcare.
Agilent Technologies Inc.
Bio-Rad Laboratories Inc.
Danaher Corporation
F. Hoffmann-La Roche AG
Illumina Inc.
LI-COR Inc.
Merck KGaA
PerkinElmer Inc.
QIAGEN N.V.
Shimadzu Corporation
Thermo Fisher Scientific Inc.
Waters Corporation
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
August 30, 2022: Thermo Fisher Scientific, Inc. launched CE-IVD (IVDD) NGS test and analysis software to expand access to personalized oncology biomarker testing. This announcement underscores the company's commitment to advancing the accessibility and accuracy of molecular diagnostics for cancer patients. The CE-IVD certification is a crucial regulatory milestone, indicating that the NGS test and associated software meet the rigorous standards required for diagnostic use in Europe. This certification ensures the reliability and consistency of the test results, making them suitable for clinical decision-making.
December 4, 2023: Agilent Technologies Inc. announced the addition of water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader. These features improve image quality and results by reducing deleterious effects on live-cell samples and enhancing clarity for thicker samples such as tissues and 3-D spheroids. Agilent Technologies Inc.'s enhancement of the BioTek Cytation C10 confocal imaging reader underscores their commitment to providing cutting-edge solutions for live-cell imaging and advancing research in 3-D biological models.
November 22, 2023: Danaher Corporation's development of a comprehensive mRNA production ecosystem strengthens its position as a leading provider of integrated solutions for the biotechnology and pharmaceutical industries, facilitating the efficient production of mRNA therapeutics at various scales.